



**Notice Regarding Disclosure of Sex Information on Preimplantation Genetic Diagnosis Results**

This notice serves to inform patients undergoing Preimplantation Genetic Diagnosis (PGD) testing at Reproductive Genetic Innovations (RGI), that the following test options may provide information about the sex of the embryos:

- Aneuploidy and/or Translocation testing, which includes analysis of Chromosomes X and Y, by the following methods of analysis:
  - Fluorescent in situ Hybridization (FISH)
  - Array Comparative Genomic Hybridization (aCGH)
  - Polymerase Chain Reaction (PCR)
  - Next Generation Sequencing (NGS)
  
- Single gene disorder/mutation testing for X-linked conditions by Polymerase Chain Reaction (PCR)

With these test options, **sex information will be disclosed on ALL reports**, unless specifically requested otherwise by the Referring Physician or In Vitro Fertilization (IVF) Center.

**Please select the appropriate statement, and sign below. RGI will make every effort to accommodate this preference:**

- I **DO** want RGI to disclose sex information on any PGD reports\*.
- I **DO NOT** want RGI to disclose sex information on any PGD reports\*.

*\*Physician preferences will apply. Please note, sex information must be disclosed for all X-linked single gene disorders.*

---

Printed Name	Signature of patient	Date
--------------	----------------------	------

---

Printed Name	Signature of partner	Date
--------------	----------------------	------